Gino Kenny (Dublin Mid West, People Before Profit Alliance)
Link to this: Individually | In context | Oireachtas source

604. To ask the Minister for Health if his attention has been drawn to the distress the parents of children with SMA are experiencing due to the delay in making the drug Spinraza available (details supplied); the steps he will take to ensure that this matter is resolved at the drugs meeting in January 2019; and if he will make a statement on the matter. [54321/18]

James Browne (Wexford, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

654. To ask the Minister for Health the position regarding the provision of a drug (details supplied) to persons with SMA; and if he will make a statement on the matter. [54491/18]

Simon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source

I propose to take Questions Nos. 545, 604 and 654 together.

The HSE has statutory responsibility for medicine pricing and reimbursement decisions, in accordance with the Health (Pricing and Supply of Medical Goods) Act 2013. The Act specifies the criteria for decisions on the reimbursement of medicines.

Nusinersen (Spinraza) is indicated for the treatment of 5q spinal muscular atrophy (SMA), a disorder characterised by progressive muscle atrophy and weakness.

An application for Nusinersen is currently undergoing assessment by the HSE.

The statutory assessment process involves a Health Technology Assessment followed by detailed consideration by the HSE expert groups on new Drug therapies, including the Technology Review Group for Rare Diseases and the HSE Drugs Committee.

The assessment focus is twofold and particularly centred on reviewing the evidence of the clinical effectiveness of this new drug therapy i.e. the benefits for patients undergoing clinical trials; and on the cost effectiveness of the product in view of the prices being charged for the drug.

The application is currently going through the final stages of assessment, and the various reports are due to be considered shortly by the HSE Leadership Team, following which the final decision will be notified.